Qualitative study of in vivo melphalan adduct formation in the rat by miniaturized column-switching liquid chromatography coupled with electrospray mass spectrometry

Journal of Mass Spectrometry

Volumn 39, Issue 1, 2004, Pages 29-37

  Van den Driessche, Bart ^a   Lemière, Filip ^a   Van Dongen, Walter ^a   Van der Linden, Annemie ^a   Esmans, Eddy L ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

2 deoxynucleoside; DNA adduct; Melphalan; Miniaturized liquid chromatography mass spectrometry; Rat

Indexed keywords

BLOOD; BONE; DNA; LIQUID CHROMATOGRAPHY; PHARMACOKINETICS;

MELPHALAN ADDUCTS;

MASS SPECTROMETRY;

MELPHALAN; NUCLEOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DNA ADDUCT; DRUG RESPONSE; DRUG STRUCTURE; DRUG TISSUE LEVEL; ELECTRONICS; ELECTROSPRAY MASS SPECTROMETRY; HYDROLYSIS; IN VIVO STUDY; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; TARGET ORGAN;

ANIMALS; BONE MARROW; CHROMATOGRAPHY, LIQUID; DNA ADDUCTS; INJECTIONS, INTRAVENOUS; KIDNEY; LIVER; MELPHALAN; MICROCHEMISTRY; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 1142287344     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.540     Document Type: Article

References (13)

1. Hoes I, Van Dongen W, Lemiere F, Esmans EL, Van Bockstaele D, Berneman ZN. Comparison between capillary and nano liquid chromatography-electrospray mass spectrometry for the analysis of minor DNA-melphalan adducts. J. Chromatogr. B 2000; 748: 197.
2. Hoes I, Lemiere F, Van Dongen W, Vanhoutte K, Esmans EL, Van Bockstaele D, Berneman Z, Deforce D, Van den Eeckhout EG. Analysis of melphalan adducts of 2′-deoxynucleotides in calf thymus DNA hydrolysates by capillary high-performance liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B 1999; 736: 43.
3. Van den Driessche B, Lemiere F, Van Dongen W, Esmans EL. Alkylation of DNA by melphalan: investigation of capillary liquid chromatography-electrospray ionization tandem mass spectrometry in the study of the adducts at the nucleoside level. J. Chromatogr. B 2003; 785: 21.
4. Gera S, Musch E, Osterheld HKO, Loos U. Relevance of the hydrolysis and protein-binding of melphalan to the treatment of multiple-myeloma. Cancer Chemother. Pharmacol. 1989; 23: 76.
5. Bauer GB, Povirk LF. Specificity and kinetics of interstrand and intrastrand bifunctional alkylation by nitrogen mustards at a G-G-C sequence. Nucleic Acids Res. 1997; 25: 1211.
6. Greene MH, Harris EL, Gershenson DM, Malkasian GD, Melton LJ, Dembo AJ, Bennett JM, Moloney WC, Boice JD. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann. Intern. Med. 1986; 105: 360.
7. Embrechts J, Lemiere F, Van Dongen W, Esmans EL. Equilenin-2 1-deoxynucleoside adducts: analysis with nano-liquid chromatography coupled to nano-electrospray tandem mass spectrometry. J. Mass Spectrom. 2001; 36: 317.
8. Ahmed AE, Hsu TF, Elazhary RA, Moawad H, Farrish HH, Costanzi J. Tissue distribution and macromolecular interactions of C-14-ring melphalan in the rat. Cancer Chemother. Pharmacol. 1982; 8: 271.
9. Vistica DT. Cytotoxicity as an indicator for transport mechanism - evidence that melphalan is transported by 2 leucine-preferring carrier system in the L1210 murine leukemia cell. Biochim. Biophys. Acta 1979; 550: 309.
10. Vistica DT, Schuette BP. Carrier mechanism and specificity accounting for the increase in intracellular melphalan by the basic amino acids. Mol. Pharmacol. 1981; 19: 92.
11. Panasci L, Henderson D, Torresgarcia SJ, Skalski V, Caplan S, Hutchinson M. Transport, metabolism, and DNA interaction of melphalan in lymphocytes. Cancer Res. 1988; 48: 1972.
12. Ahmed AE, Hsu TF, Elazhary RA, Moawad H, Costanzi J. Macromolecular interactions of C-14-labeled ring-melphalan in blood. Biochem. Pharmacol. 1982; 31: 1615.
13. Hemminki K, Koskinen M, Rajaniemi H, Zhao C. DNA adducts, mutations, and cancer 2000. Regul. Toxicol. Pharmacol. 2000; 32: 264.